141 related articles for article (PubMed ID: 28878018)
1. A rational approach to enhancing antibody Fc homodimer formation for robust production of antibody mixture in a single cell line.
Yu J; Wang X; Xu T; Jin Q; Duan J; Wu J; Wu H; Xu T; Ye S
J Biol Chem; 2017 Oct; 292(43):17885-17896. PubMed ID: 28878018
[TBL] [Abstract][Full Text] [Related]
2. Engineering of Immunoglobulin Fc Heterodimers Using Yeast Surface-Displayed Combinatorial Fc Library Screening.
Choi HJ; Kim YJ; Choi DK; Kim YS
PLoS One; 2015; 10(12):e0145349. PubMed ID: 26675656
[TBL] [Abstract][Full Text] [Related]
3. Crystal structures of immunoglobulin Fc heterodimers reveal the molecular basis for heterodimer formation.
Choi HJ; Seok SH; Kim YJ; Seo MD; Kim YS
Mol Immunol; 2015 Jun; 65(2):377-83. PubMed ID: 25743157
[TBL] [Abstract][Full Text] [Related]
4. Structural differences between glycosylated, disulfide-linked heterodimeric Knob-into-Hole Fc fragment and its homodimeric Knob-Knob and Hole-Hole side products.
Kuglstatter A; Stihle M; Neumann C; Müller C; Schaefer W; Klein C; Benz J;
Protein Eng Des Sel; 2017 Sep; 30(9):649-656. PubMed ID: 28985438
[TBL] [Abstract][Full Text] [Related]
5. Immunoglobulin domain interface exchange as a platform technology for the generation of Fc heterodimers and bispecific antibodies.
Skegro D; Stutz C; Ollier R; Svensson E; Wassmann P; Bourquin F; Monney T; Gn S; Blein S
J Biol Chem; 2017 Jun; 292(23):9745-9759. PubMed ID: 28450393
[TBL] [Abstract][Full Text] [Related]
6. Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG.
Gunasekaran K; Pentony M; Shen M; Garrett L; Forte C; Woodward A; Ng SB; Born T; Retter M; Manchulenko K; Sweet H; Foltz IN; Wittekind M; Yan W
J Biol Chem; 2010 Jun; 285(25):19637-46. PubMed ID: 20400508
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive elucidation of the structural and functional roles of engineered disulfide bonds in antibody Fc fragment.
Zeng F; Yang C; Gao X; Li X; Zhang Z; Gong R
J Biol Chem; 2018 Dec; 293(49):19127-19135. PubMed ID: 30327432
[TBL] [Abstract][Full Text] [Related]
8. A heterodimeric Fc-based bispecific antibody simultaneously targeting VEGFR-2 and Met exhibits potent antitumor activity.
Choi HJ; Kim YJ; Lee S; Kim YS
Mol Cancer Ther; 2013 Dec; 12(12):2748-59. PubMed ID: 24132142
[TBL] [Abstract][Full Text] [Related]
9. Antiparallel conformation of knob and hole aglycosylated half-antibody homodimers is mediated by a CH2-CH3 hydrophobic interaction.
Elliott JM; Ultsch M; Lee J; Tong R; Takeda K; Spiess C; Eigenbrot C; Scheer JM
J Mol Biol; 2014 May; 426(9):1947-57. PubMed ID: 24576605
[TBL] [Abstract][Full Text] [Related]
10. Computationally Designed Bispecific Antibodies using Negative State Repertoires.
Leaver-Fay A; Froning KJ; Atwell S; Aldaz H; Pustilnik A; Lu F; Huang F; Yuan R; Hassanali S; Chamberlain AK; Fitchett JR; Demarest SJ; Kuhlman B
Structure; 2016 Apr; 24(4):641-651. PubMed ID: 26996964
[TBL] [Abstract][Full Text] [Related]
11. Human epidermal growth factor receptor (HER-1:HER-3) Fc-mediated heterodimer has broad antiproliferative activity in vitro and in human tumor xenografts.
Sarup J; Jin P; Turin L; Bai X; Beryt M; Brdlik C; Higaki JN; Jorgensen B; Lau FW; Lindley P; Liu J; Ni I; Rozzelle J; Kumari R; Watson SA; Zhang J; Shepard HM
Mol Cancer Ther; 2008 Oct; 7(10):3223-36. PubMed ID: 18852126
[TBL] [Abstract][Full Text] [Related]
12. Structural basis of a novel heterodimeric Fc for bispecific antibody production.
Wei H; Cai H; Jin Y; Wang P; Zhang Q; Lin Y; Wang W; Cheng J; Zeng N; Xu T; Zhou A
Oncotarget; 2017 Aug; 8(31):51037-51049. PubMed ID: 28881627
[TBL] [Abstract][Full Text] [Related]
13. A single mutation increases heavy-chain heterodimer assembly of bispecific antibodies by inducing structural disorder in one homodimer species.
Stutz C; Blein S
J Biol Chem; 2020 Jul; 295(28):9392-9408. PubMed ID: 32404368
[TBL] [Abstract][Full Text] [Related]
14. Charge-mediated Fab-Fc interactions in an IgG1 antibody induce reversible self-association, cluster formation, and elevated viscosity.
Arora J; Hu Y; Esfandiary R; Sathish HA; Bishop SM; Joshi SB; Middaugh CR; Volkin DB; Weis DD
MAbs; 2016; 8(8):1561-1574. PubMed ID: 27560842
[TBL] [Abstract][Full Text] [Related]
15. Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins.
Ha JH; Kim JE; Kim YS
Front Immunol; 2016; 7():394. PubMed ID: 27766096
[TBL] [Abstract][Full Text] [Related]
16. IgG2 Fc structure and the dynamic features of the IgG CH2-CH3 interface.
Teplyakov A; Zhao Y; Malia TJ; Obmolova G; Gilliland GL
Mol Immunol; 2013 Nov; 56(1-2):131-9. PubMed ID: 23628091
[TBL] [Abstract][Full Text] [Related]
17. Structural characterization of GASDALIE Fc bound to the activating Fc receptor FcγRIIIa.
Ahmed AA; Keremane SR; Vielmetter J; Bjorkman PJ
J Struct Biol; 2016 Apr; 194(1):78-89. PubMed ID: 26850169
[TBL] [Abstract][Full Text] [Related]
18. Boosting half-life and effector functions of therapeutic antibodies by Fc-engineering: An interaction-function review.
Fonseca MHG; Furtado GP; Bezerra MRL; Pontes LQ; Fernandes CFC
Int J Biol Macromol; 2018 Nov; 119():306-311. PubMed ID: 30041038
[TBL] [Abstract][Full Text] [Related]
19. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies.
Davis JH; Aperlo C; Li Y; Kurosawa E; Lan Y; Lo KM; Huston JS
Protein Eng Des Sel; 2010 Apr; 23(4):195-202. PubMed ID: 20299542
[TBL] [Abstract][Full Text] [Related]
20. Restricted processing of CD16a/Fc γ receptor IIIa
Patel KR; Roberts JT; Subedi GP; Barb AW
J Biol Chem; 2018 Mar; 293(10):3477-3489. PubMed ID: 29330305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]